Skip to main content
Premium Trial:

Request an Annual Quote

Enpicom, MiLaboratories Partner on Immune Repertoire Sequencing Software Integration

NEW YORK – Enpicom and MiLaboratories on Tuesday announced a strategic partnership to integrate MiLaboratories' MiXCR immune repertoire sequencing software into Enpicom's ImmunoGenomix (IGX) bioinformatics platform.

Integrating the MiLaboratories software "really contributes to the adoption of professional repertoire sequencing data management and analysis," Enpicom CEO Jos Lunenberg said in a statement. "We look forward to jointly start serving customers shortly and further expanding our collaboration with MiLaboratories in the near future."

"With this integration, we intend to expand [MiXCR's] usability with embedding management, annotation, visualization, and sharing capabilities into repertoire sequencing analysis workflows," MiLaboratories CEO Yuri Nikolsky said in a statement. "This enables customers to obtain more insights from their next-generation sequencing data, adding significant value in drug discovery, development, and academic environments."

Financial and other terms of the deal were not disclosed.

Based in s’Hertogenbosch, the Netherlands, Enpicom offers the IGX platform to manage, store, analyze, visualize, and interpret T and B cell repertoire sequencing data.

Solana Beach, California-based MiLaboratories offers a human T cell receptor profiling kit, immune cell profiling services, and software tools and algorithms to analyze immune cell profiles.

In December 2019, Enpicom partnered with Cytura Therapeutics to develop an NGS-based cancer diagnostic quantifying mutations that cause genome instability.

And in August of last year, MiLaboratories collaborated with MIODx on immune repertoire profiling in the US and Europe.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.